Connect with us

Technology

Boro Dropulic to Share Pivotal Insights at Advanced Therapies Week on January 21-22, 2025

Published

on

GAITHERSBURG, Md., Jan. 17, 2025 /PRNewswire/ — Caring Cross and Vector BioMed, Inc. are pleased to announce that Boro Dropulic, Executive Director of Caring Cross and CEO of Vector BioMed, will be speaking at Advanced Therapies Week (ATW) on January 21 and 22 in Dallas, Texas. Dr. Dropulic will participate in three key sessions where he will share his expertise and insights into the future of cell and gene therapies, strategies for improving access, and the commercialization of innovative therapeutics.

Session Details

Plenary Panel: “Innovating for the Future of Cell and Gene Therapies”
Date: January 21, 2025
Time: 9:00 – 10:30 CST
Highlights: Dr. Dropulic will join an esteemed panel to explore challenges and solutions for advancing the next generation of cell and gene therapies.

Panel Discussion: “The CAR-T Story and the Future of Cell Therapies”
Date: January 21, 2025
Session Timing: 13:15 – 14:15 CST
Overview: Delve into the CAR-T journey, including technological advancements and innovations shaping the landscape of cellular therapies.

Workshop: “Transforming Good Science into Sustainable Business: Actionable Strategies for Commercializing Cell and Gene Therapies”
Date: January 22, 2025
Time: 8:00 – 9:00 CST
Format: A hands-on session where Dr. Dropulic will outline pathways for converting scientific innovation into scalable and accessible commercial solutions.

Thought Leadership from Dr. Boro Dropulic

Dr. Dropulic will address pressing issues such as the high cost of CAR-T and other cellular therapies, the importance of point-of-care manufacturing, and the global push to localize development and production:

Reducing Manufacturing Costs: Lowering the cost of materials, particularly lentiviral vectors, is critical to making therapies accessible. Vector BioMed is leading the way, offering GMP-grade lentiviral vectors at approximately half the price of leading alternatives through innovative and efficient manufacturing processes.Point-of-Care Manufacturing: Centralized manufacturing models are costly and inefficient. Distributing manufacturing directly to care facilities can reduce costs and ensure that transformative therapies reach more patients in need.

Global Access: Empowering low- and middle-income countries (LMICs) to develop and manufacture advanced therapeutics will address disparities in healthcare access and drive meaningful change. Caring Cross’s initiatives and international networks aim to localize production capabilities and enable affordable treatments for underserved regions.

Caring Cross: Building a Global Network for Advanced Therapeutics

Through its International Affordable Advanced Therapeutics Manufacturing Network, Caring Cross partners with organizations worldwide to enhance point-of-care, low-cost manufacturing of cellular therapeutics. This network promotes equity, inclusiveness, and sustainability by:

Strengthening manufacturing capacity and clinical trial infrastructure.Expanding collaboration and visibility for member organizations.Enabling transparent and responsive manufacturing practices.

By addressing these needs, the network empowers organizations to serve diverse populations and contribute to the equitable development and distribution of lifesaving therapies.

Vector BioMed: Transforming Lentiviral Vector Development and Rapid Production

Vector BioMed continues to expand its development resources and optimize lentiviral vector manufacturing. The company is focused on:

Disrupting traditional workflows to offer cost-effective solutions.Refining vector design during early development for enhanced efficiency.Continuing innovation: Later in 2025, Vector BioMed plans to launch several new products as part of a notable expansion of its premier lentiviral vector platform technology.

With these advancements, Vector BioMed is committed to driving innovation while maintaining an unwavering focus on cost reduction for its clients.

Connect with Caring Cross and Vector BioMed at ATW

Learn more about Vector BioMed’s lentiviral vector services at Vector BioMed.
Discover how Caring Cross is advancing global access to therapies at Caring Cross.

Request a meeting with team members at ATW using the ATW Event App (link), our contact form, or via email at partner@vectorbiomed.com.

View original content:https://www.prnewswire.com/news-releases/boro-dropulic-to-share-pivotal-insights-at-advanced-therapies-week-on-january-21-22-2025-302354603.html

SOURCE Caring Cross

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Mastech Digital to Announce Second Quarter 2026 Financial Results; Participate in Upcoming Investor Conference

Published

on

By

PITTSBURGH, July 24, 2026 /PRNewswire/ — Mastech Digital, Inc. (NYSE American: MHH) (“Mastech Digital”), a leading provider of Digital Transformation IT Services, today announced the date for the release of its financial results for the second quarter ended June 30, 2026, and its participation in an upcoming investor conference.

Second Quarter 2026 Earnings:

Mastech Digital will report its financial results for the second quarter 2026 before the market opens on Thursday, August 6, 2026. Management will host a live conference call and webcast at 9:00 a.m. Eastern Time on that day to discuss the Company’s financial performance and operating results.  The conference call will be hosted by Nirav Patel, President and CEO, and Kannan Sugantharaman, Chief Financial and Operations Officer.

Those wishing to participate via webcast should access the call through Mastech Digital’s Investor Relations website at https://investors.mastechdigital.com. Those wishing to participate via telephone may dial in at 1-800-715-9871 (USA) or 1-646-307-1963 (International) with the passcode 7506988. The replay will be available via webcast through Mastech Digital’s Investor Relations website.

Upcoming Investor Conference:

Mr. Sugantharaman will host a fireside chat at the Sidoti Micro-Cap Investor Conference on Wednesday, August 19, 2026, at 9:15 a.m. Eastern Time.

Mastech Digital management is scheduled to host virtual one-on-one and small group meetings with investors during the conference on August 19-20, 2026. Investors interested in arranging a meeting should contact their Sidoti representative or reach out to the Mastech Digital investor relations team at investors@mastechdigital.com.

About Mastech Digital, Inc.

Mastech Digital (NYSE American: MHH) is a leading provider of Digital Transformation IT Services. The Company offers Data Management, Analytics & AI Solutions, and IT Staffing Services with a digital-first approach. A minority-owned enterprise, Mastech Digital is headquartered in Pittsburgh, PA, with offices across the U.S., Canada, Europe, and India. Visit us at www.mastechdigital.com.

Investor Relations Contact:
investors@mastechdigital.com 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/mastech-digital-to-announce-second-quarter-2026-financial-results-participate-in-upcoming-investor-conference-302834421.html

SOURCE Mastech Digital, Inc.

Continue Reading

Technology

SOLAI Limited Announces Extraordinary General Meeting

Published

on

By

AKRON, Ohio, July 24, 2026 /PRNewswire/ — SOLAI Limited (NYSE: SLAI) (“SOLAI” or the “Company”) (previously known as “BIT Mining Limited”), a technology-driven personal AI and digital infrastructure provider, today announced that it will hold its extraordinary general meeting of shareholders at 428 South Seiberling Street, Akron, Ohio, US on August 14, 2026 at 10:00 a.m., New York time.

Holders of record of ordinary shares and preference shares of the Company at the close of business on July 20, 2026, New York time (the “Record Date”) are entitled to receive notice of, and to attend and vote at, the extraordinary general meeting or any adjournment thereof. Holders of the Company’s American Depositary Shares (“ADSs”) who wish to exercise their voting rights for the underlying ordinary shares must act through the depositary of the Company’s ADS program, Deutsche Bank Trust Company Americas.

The notice of the extraordinary general meeting, which sets forth the resolutions to be submitted to shareholder approval at the extraordinary general meeting is available on the Investor Relations section of the Company’s website at https://ir.solai.com

About SOLAI Limited

SOLAI Limited (previously known as “BIT Mining Limited”) (NYSE: SLAI) (previously traded under “BTCM”) is a technology-driven personal AI and digital infrastructure provider. Building upon its historical legacy in digital asset mining and blockchain network operations, the Company is leveraging extensive experience in large-scale hardware deployment, data center operations, and high-performance computing to build the foundational infrastructure for personal AI computing and digital asset ecosystems globally.

For more information:

SOLAI Limited
ir@solai.com
ir.solai.com
www.solai.com 

Christensen Advisory
Jason Ng
Tel: +852-2117-0861
Email: solai@christensencomms.com 

 

View original content:https://www.prnewswire.com/news-releases/solai-limited-announces-extraordinary-general-meeting-302834034.html

SOURCE SOLAI Limited

Continue Reading

Technology

/U P D A T E — TrendAI/

Published

on

By

This release has been updated to include new information provided by TrendAI. The complete, corrected release follows, with additional details at the end:

TrendAI™ Adopts Claude Opus 5 to Advance Vulnerability Prioritization and Virtual Patching

As a participant in Anthropic’s Cyber Verification Program, TrendAI applies frontier reasoning to convert vulnerability intelligence into faster protection across hybrid environments

DALLAS, July 24, 2026 /PRNewswire/ — TrendAI™, the enterprise AI security leader from Trend Micro Incorporated (TYO: 4704; TSE: 4704), today announced it is adopting Claude Opus 5, Anthropic’s latest and most capable Opus model, to help security teams convert vulnerability intelligence into immediate protection, from prioritization to virtual patching. The move builds on TrendAI’s collaboration with Anthropic on Claude Opus 4.8, extending the same defensive focus to a model that delivers step-change gains in advanced reasoning, agentic workflows, and long-horizon analysis. As AI makes finding vulnerabilities easier than ever, the harder problem becomes protecting organizations faster than software can be permanently patched, and that is where TrendAI is putting Opus 5 to work.

As a participant in Anthropic’s Cyber Verification Program, which credentials organizations for the defensive use of frontier AI models, TrendAI is positioned to apply Claude Opus 5 to defensive security as access becomes available. The model is Zero Data Retention compatible, supporting TrendAI’s governance and data-protection requirements as it scales AI across security operations.

The work extends to TrendAI Threat Research, where frontier AI models are combined with our proprietary frontier intelligence engine and human expertise to generate pre-disclosure intelligence. Those insights power TrendAI Vision One™, delivering stronger detection, deeper forensic insights, and proactive protection through virtual patching.

Rachel Jin, Chief Platform and Business Officer, Head of TrendAI™:
“With Claude Opus 5, TrendAI can move from vulnerability intelligence to action faster than ever, prioritizing what matters most by exploitability and business impact. Finding the vulnerability was always the hard part. Now the challenge is protecting organizations faster than software can be permanently patched, and frontier reasoning is what changes that equation, extending all the way to virtual patching that protects customers before a vendor fix ships. This is what it means to secure the AI age, fearlessly.”

These capabilities support TrendAI Vision One™ in helping security analysts, AppSec teams, and SOC teams prioritize exposure, map attack paths, and accelerate mitigation, including virtual patching, across hybrid environments, moving vulnerability management from a static scanning process into a faster, context-aware risk mitigation workflow.

About TrendAI™
TrendAI™, the global AI security leader and enterprise business unit of Trend Micro, empowers organizations with full AI visibility and consolidated security that inspires confidence, drives innovation, and eliminates risk. Trusted by the largest enterprises and governments across 185 countries, TrendAI™ secures the entire organization, from identities, to infrastructure, to data. Global Fortune 500 companies rely on TrendAI™ to cut risk and stop threats up to three months earlier, powered by world-leading threat and attack intelligence. Through deep ecosystem partnerships with market leaders like NVIDIA, Anthropic, AWS, Google, and Microsoft, TrendAI™ empowers your organization to securely drive forward at the speed of AI. AI Fearlessly. Learn more: trendaisecurity.com

About Anthropic
Anthropic is an AI safety and research company dedicated to building reliable, interpretable, and steerable AI systems. Its Claude family of models, including Claude Opus 5, enables advanced capabilities across a wide range of applications, including code understanding and security analysis.

Update: The latest version of this release includes additional statements from TrendAI related to the original announcement.

View original content to download multimedia:https://www.prnewswire.com/news-releases/trendai-adopts-claude-opus-5-to-advance-vulnerability-prioritization-assessment-and-virtual-patching-302834362.html

SOURCE TrendAI

Continue Reading

Trending